These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 35642907)

  • 1. Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan.
    Bardia A; Harnden K; Mauro L; Pennisi A; Armitage M; Soliman H
    Oncologist; 2022 Aug; 27(8):637-645. PubMed ID: 35642907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
    Rugo HS; Bianchini G; Cortes J; Henning JW; Untch M
    ESMO Open; 2022 Aug; 7(4):100553. PubMed ID: 35964548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study.
    Modi S
    Future Oncol; 2021 Sep; 17(26):3415-3423. PubMed ID: 34263665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01).
    Saura C; Modi S; Krop I; Park YH; Kim SB; Tamura K; Iwata H; Tsurutani J; Sohn J; Mathias E; Liu Y; Cathcart J; Singh J; Yamashita T
    Ann Oncol; 2024 Mar; 35(3):302-307. PubMed ID: 38092229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
    Lee J; Park YH
    Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan.
    Yin O; Iwata H; Lin CC; Tamura K; Watanabe J; Wada R; Kastrissios H; AbuTarif M; Garimella T; Lee C; Zhang L; Shahidi J; LaCreta F
    Clin Pharmacol Ther; 2021 Oct; 110(4):986-996. PubMed ID: 33999422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
    Modi S; Saura C; Yamashita T; Park YH; Kim SB; Tamura K; Andre F; Iwata H; Ito Y; Tsurutani J; Sohn J; Denduluri N; Perrin C; Aogi K; Tokunaga E; Im SA; Lee KS; Hurvitz SA; Cortes J; Lee C; Chen S; Zhang L; Shahidi J; Yver A; Krop I;
    N Engl J Med; 2020 Feb; 382(7):610-621. PubMed ID: 31825192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
    Petit T; Hajjaji N; Antoine EC; Benderra MA; Gozy M; Foa C; Mouysset JL; Grenier J; Mousseau M; Mailliez A; Saghatchian M; Lachaier E; Desmoulins I; Hennequin A; Maes P; Loirat D; Ricci F; Diéras V; Berton D; Tiong FL; Teixeira L; Dohollou N; Lévy C; Bachelot T; Pierga JY
    Cancer Med; 2024 May; 13(9):e7168. PubMed ID: 38733172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
    Botticelli A; Caputo R; Scagnoli S; Pisegna S; De Laurentiis M; Curigliano G; Lambertini M; Pantano F; Palazzo A; Paris I; Vernieri C; Tedesco B; Giampaglia M; Palleschi M; Ballatore Z; Alesini D; D'Auria G; Fabbri A; Rossi L; Verrazzo A; Scafetta R; Marinelli D; Sposetti C; Barberi V; Strigari L; Marchetti P; Santini D; Fabi A
    Oncologist; 2024 Apr; 29(4):303-310. PubMed ID: 37995313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer.
    Rugo HS; Crossno CL; Gesthalter YB; Kelley K; Moore HB; Rimawi MF; Westbrook KE; Buys SS
    JCO Oncol Pract; 2023 Aug; 19(8):539-546. PubMed ID: 37207306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer.
    Mishima S; Shitara K
    Expert Opin Biol Ther; 2021 Jul; 21(7):825-830. PubMed ID: 33798395
    [No Abstract]   [Full Text] [Related]  

  • 12. A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer.
    Nguyen X; Hooper M; Borlagdan JP; Palumbo A
    Ann Pharmacother; 2021 Nov; 55(11):1410-1418. PubMed ID: 33629601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer.
    Bartsch R
    Expert Opin Investig Drugs; 2020 Sep; 29(9):901-910. PubMed ID: 32701032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan.
    Ali A; Graff SL
    Curr Oncol Rep; 2024 Jan; 26(1):1-9. PubMed ID: 38091201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
    Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S
    J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition)].
    Trastuzumab Deruxtecan Clinical Management Pathway and Adverse Reaction Management Consensus Expert Group
    Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):304-318. PubMed ID: 38644266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer.
    Shitara K; Baba E; Fujitani K; Oki E; Fujii S; Yamaguchi K
    Gastric Cancer; 2021 Jul; 24(4):780-789. PubMed ID: 33997928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer.
    Nie T; Blair HA
    Target Oncol; 2023 May; 18(3):463-470. PubMed ID: 37129796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
    Schreiber AR; O'Bryant CL; Kabos P; Diamond JR
    Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
    Adams E; Wildiers H; Neven P; Punie K
    ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.